Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics reported positive 12-week induction data from Part A of the Phase 2 SKYLINE trial for SPY002, an anti-TL1A antibody for ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.7-point reduction in Robart’s Histopathology Index (RHI) score (p<0.0001), alongside 33% clinical remission and 42% endoscopic improvement rates.
Key figures
- Drug Name
- SPY002
- Phase Of Trial
- Phase 2
- P value
- <0.0001
- Sae rate
- 4.2%
- Teae rate
- 41.7%
- Rhi reduction
- -10.7
- Study population size
- 48
- Clinical remission rate
- 33%
- Modified mayo score change
- -3.7
- Endoscopic improvement rate
- 42%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.